Proposal: Standardized Autoimmune and Post-Viral Disease Detection, Testing, and Reporting Initiative

By

Executive Summary

We propose the creation of a standardized national or international research framework for patients with suspected autoimmune, post-viral, ME/CFS, Long COVID, dysautonomia, and related conditions. The initiative would combine systematic biological testing, genetic and epigenetic evaluation, and centralized clinical data collection to accelerate the discovery of disease mechanisms, biomarkers, and targeted treatments.

The central premise is straightforward: if every patient with suspected autoimmune or post-infectious illness were evaluated using a standardized testing protocol and their clinical information were entered into a shared research database, the pace of scientific discovery could increase dramatically. Data collection could occur in primary care physician (PCP) offices, hospital systems, specialty clinics, academic medical centers, and designated research groups, ensuring broad participation and comprehensive patient representation.

Background

One of the greatest barriers to progress in these conditions is fragmentation. Currently:

  • Different clinics test different autoantibodies and biomarkers.
  • Many potentially relevant autoantibodies are never measured.
  • Genetic predispositions and known epigenetic markers are not consistently evaluated.
  • Symptom descriptions vary significantly between providers and institutions.
  • Clinical and laboratory data remain isolated within PCP practices, hospitals, specialty centers, laboratories, and research groups.
  • Researchers often rely on relatively small cohorts despite these illnesses affecting millions of people worldwide.

As a result, important biological patterns may remain undetected for years.

Proposed Solution

Establish a standardized detection and reporting system in which patients with suspected autoimmune, post-viral, ME/CFS, Long COVID, dysautonomia, or related disorders undergo comprehensive and standardized evaluation regardless of whether they are seen in:

  • Primary Care Physician (PCP) offices
  • Hospital systems
  • Specialty clinics
  • Academic medical centers
  • Community health centers
  • Designated research institutions and clinical research networks

Participating facilities would collect standardized clinical and biological data and contribute de-identified information to a centralized research registry.

Standardized Biological Testing

Including, but not limited to:

  • Broad autoantibody panels
  • Cytokine and inflammatory marker testing
  • T-cell and B-cell profiling
  • Immune function testing
  • Metabolomic assessments
  • Infection and exposure history
  • Autonomic testing
  • Imaging studies, where appropriate

Genetic and Epigenetic Assessment

Including:

  • Family history of autoimmune, neurological, and post-infectious disorders
  • Known genetic risk factors associated with autoimmune disease
  • HLA typing and other relevant immune-related genetic markers
  • Whole genome or exome sequencing where appropriate
  • Assessment of known epigenetic signatures associated with immune dysregulation, chronic inflammation, or post-viral illness
  • Documentation of inherited predispositions that may influence disease development, severity, or treatment response

Genetic and epigenetic information could help identify individuals at elevated risk, reveal inherited susceptibility patterns, and improve disease classification by distinguishing biologically distinct subgroups.

Standardized Clinical Data Collection

Including:

  • Detailed symptom profiles
  • Disease onset and progression
  • Functional status measures
  • Family medical history
  • Environmental and infectious exposures
  • Laboratory findings
  • Treatment history
  • Treatment responses
  • Longitudinal follow-up assessments

To ensure consistency, standardized symptom questionnaires and reporting criteria would be used across all participating PCP offices, hospitals, specialty clinics, and research centers.

Centralized Research Registry

All de-identified data would be entered into a secure, standardized database accessible to qualified researchers. The registry would support large-scale analysis while maintaining patient privacy and regulatory compliance.

By integrating data from frontline PCP practices, hospital systems, specialty clinics, and designated research groups, the registry could capture a much broader and more representative patient population than traditional research studies.

Expected Benefits

1. Accelerated Identification of Disease Subtypes

Many patients currently grouped under the same diagnosis may actually represent multiple biologically distinct conditions.

For example:

  • One subgroup may exhibit GPCR autoantibodies.
  • Another may have neuronal autoantibodies.
  • Another may have specific genetic susceptibility markers.
  • Another may demonstrate unique epigenetic signatures despite normal conventional testing.
  • Others may show no detectable autoantibodies but possess distinct immune abnormalities.

Large datasets would enable researchers to identify these subtypes far more rapidly than is currently possible.

2. Discovery of Biomarkers

When biological, genetic, epigenetic, and clinical data from tens or hundreds of thousands of patients are analyzed together, meaningful associations become easier to detect.

Researchers could identify biomarkers linked to specific symptom clusters such as:

  • Orthostatic intolerance
  • Post-exertional malaise
  • Cognitive dysfunction
  • Neuropathic pain
  • Gastrointestinal symptoms
  • Fatigue severity

Biomarkers that remain statistically invisible in small studies may become readily apparent at scale.

3. Improved Diagnostic Accuracy

The integration of autoantibody testing, genetic risk factors, epigenetic markers, and clinical presentation could lead to more objective diagnostic criteria.

Rather than relying primarily on symptom-based diagnoses, clinicians could identify patients based on measurable biological characteristics, reducing diagnostic delays and misclassification.

4. Precision Treatment Development

The registry would support a shift from diagnosis-based treatment evaluation to biology-based treatment evaluation.

Instead of asking:

"Does this treatment work for ME/CFS?"

Researchers could ask:

"Does this treatment work for patients with this specific antibody profile, genetic predisposition, epigenetic signature, or immune phenotype?"

This approach could uncover treatment benefits that are currently obscured by the biological heterogeneity within existing diagnostic categories.

5. Longitudinal Disease Tracking

Repeated measurements over time would allow researchers to determine:

  • Whether specific antibodies appear before symptom worsening
  • Whether genetic or epigenetic patterns predict disease progression
  • Whether biomarkers correlate with disease severity
  • Whether biological abnormalities improve alongside clinical recovery
  • Which markers are associated with long-term outcomes

Such data are critical for distinguishing correlation from potential disease causation.

6. Cross-Disease Comparison

A centralized registry would allow direct comparison across related conditions, including:

  • Long COVID
  • ME/CFS
  • POTS
  • Fibromyalgia
  • Sjögren's syndrome
  • Lupus
  • Small fiber neuropathy
  • Other autoimmune and post-infectious disorders

Identifying shared biomarkers, genetic risk factors, and epigenetic patterns could reveal common mechanisms and support the development of treatments applicable across multiple conditions.

Rationale

Large-scale registries have transformed numerous areas of medicine, including cancer research, genetics, and rare diseases. Once sufficient standardized biological and clinical data become available, discoveries that previously required decades can often be achieved within a few years.

Modern machine learning, network analysis, and advanced statistical methods are particularly effective when applied to large, well-structured datasets. Integrating data from PCP clinical settings, hospitals, specialty centers, and designated research groups would provide the scale necessary to uncover disease mechanisms that are currently hidden by fragmented data collection.

Conclusion

Current diagnostic categories for autoimmune, post-viral, and complex chronic illnesses likely encompass multiple underlying biological conditions. A standardized detection, testing, genetic and epigenetic evaluation, and reporting initiative—implemented across PCP offices, hospitals, specialty clinics, and designated research institutions—would create the scale and consistency necessary to uncover these hidden subgroups, identify reliable biomarkers, and accelerate the development of targeted therapies.

By combining systematic biological testing, inherited genetic risk assessment, epigenetic profiling, and high-quality longitudinal clinical data within a centralized research registry, the medical and scientific community could transform fragmented observations into actionable discoveries, leading to more precise diagnoses, more effective treatments, and a deeper understanding of autoimmune and post-viral diseases.

© 2000-2030 Sieglinde W. Alexander. All writings by Sieglinde W. Alexander have a five-year copyright. Library of Congress Card Number: LCN 00-192742 ISBN: 0-9703195-0-9  

Comments

Post a Comment

Popular posts from this blog

Schnitzler Syndrome: A Rare Autoinflammatory Disorder

By
Schnitzler syndrome is a rare, chronic autoinflammatory disease characterized by chronic urticaria (hives), recurrent fever, joint pain, and monoclonal gammopathy (abnormal proteins in the blood). First described by Dr. Liliane Schnitzler in 1972 , this condition is often misdiagnosed, leading to years of untreated symptoms before a correct diagnosis is made. The case report, " A 58-Year-Old Woman With Urticaria, Fever, and Joint Pain " , describes a case that closely aligns with my own experience with this challenging disorder. Key Features of Schnitzler Syndrome Schnitzler syndrome presents with a characteristic set of symptoms, though not all patients experience them in the same way: Chronic Urticaria (Hives) – Persistent, non-itchy or mildly itchy red patches that do not respond to antihistamines. Monoclonal Gammopathy (IgM or IgG type) – Abnormal monoclonal immunoglobulin detected in the blood (most commonly IgM ). Recurrent Fever – Unexplained fever episodes, often...
Read more

Acute Flaccid Myelitis (AFM): Understanding the “Polio-like” Illness Affecting the Spinal Cord

By
Acute flaccid myelitis (AFM) is a rare but serious neurological disorder that primarily affects children and results in sudden weakness or paralysis in the limbs. Often referred to as a “polio-like” illness, AFM has drawn growing attention over the past decade due to its similarities with poliomyelitis and its seasonal spikes in reported cases. While AFM remains uncommon, its potential severity—and the uncertainty surrounding its causes—make it an important condition for clinicians, parents, and public health officials to understand. What Is Acute Flaccid Myelitis? AFM is a condition that affects the gray matter of the spinal cord , where it damages motor neurons responsible for muscle movement. This leads to acute, flaccid paralysis , meaning muscles become limp and weak, often without warning. The condition can progress rapidly, and in some cases, the weakness can become long-lasting or even permanent. Although its symptoms resemble those of poliovirus infection, AFM is not cau...
Read more

Dysferlin Protein: Key Roles, Genetic Locations

By
Image
The purpose of this article is to share and discuss the details of a new discovery, which is highlighted within: CRISPR-Cas9: A Breakthrough Tool to Repair the DYSF Gene The dysferlin protein plays an essential role in maintaining the integrity of muscle cell membranes, particularly in tissues that endure significant mechanical stress, such as skeletal and cardiac muscles . Encoded by the DYSF gene , dysferlin is indispensable for repairing damaged cell membranes after injury caused by muscle contraction or external forces. This article explores the main locations where dysferlin is produced, its role in muscle repair, and supportive nutritional and therapeutic strategies for individuals with dysferlin deficiency, such as those affected by dysferlinopathies (e.g., Limb-Girdle Muscular Dystrophy Type 2B or Miyoshi Myopathy). Currently, there is no definitive answer as to why the severity of dysferlin protein expression or depletion varies. Do pathogens play a role in the methylation o...
Read more

Very Long-Chain Fatty Acids (VLCFAs) X-ALD and Spinal Muscular Atrophy (SMA): Exploring the Connection

By
Image
Introduction: White Brain Matter, VLCFAs, and X-ALD X-linked Adrenoleukodystrophy (X-ALD) is a rare inherited metabolic disorder and a major cause of progressive neurodegeneration in children—sometimes referred to as “childhood dementia.” Across related conditions, prevalence can range from approximately 1 in 2,000 to 1 in 500,000 newborns. Among its forms, childhood cerebral X-ALD is the most severe, marked by rapid inflammatory demyelination in the brain and often fatal outcomes if not treated early. At the core of X-ALD is a disruption in the metabolism of Very Long-Chain Fatty Acids (VLCFAs). Normally, these fatty acids are broken down in peroxisomes—specialized structures within cells that help maintain metabolic balance. In X-ALD, a mutation in the ABCD1 gene impairs this function, causing VLCFAs to accumulate, particularly in the white matter of the brain, spinal cord, and adrenal glands. This accumulation leads to demyelination, adrenal insufficiency (Addison’s disease), an...
Read more

Toxic Skin Condition Post-mRNA COVID-19 Vaccination

By
Image
Important update: My experiences have now been formally verified following several years of dismissal. Vasculitis syndromes: the pathogenic roles of COVID-19 and related vaccinations https://link.springer.com/article/10.1186/s12985-025-03032-x  ----------------------------------------- Identifying Severe Skin Conditions Post-Vaccination Following administration of the BioNTech mRNA vaccine, a small subset of individuals may develop severe and complex reactions. These reactions are often misdiagnosed or misunderstood due to their rarity and diverse presentation. This essay examines a case characterized by severe skin conditions, systemic symptoms, and complications such as hypercalcemia and crystal formation. It highlights the need for accurate diagnosis, holistic management, and increased awareness of these rare but significant vaccine-related adverse events. Initial Symptoms and Misdiagnoses Severe symptoms began shortly after the first dose of the BioNTech vaccine, initially pres...
Read more

Is ME CFS connected to Spinal Muscular Atrophy (SMA) or Post Polio?

By
Today, I understand why Spinal Muscular Atrophy (SMA) received little attention, particularly in the mid-50s. This complex and debilitating genetic illness was poorly understood, and patients' symptoms were often minimized or even dismissed. For more information, please visit the Spinal Muscular Atrophy (SMA) page on MalaCards . Even now, many neurologists lack detailed knowledge of SMA, and comprehensive examinations mentioned in research are rarely pursued. In 2008, while investigating permanent adrenal insufficiency, an MRI ordered by my endocrinologist unexpectedly revealed Chiari Malformation II. However, surgery in 2009 brought no improvement. In 2010, a DNA test showed a genetic marker in the ACTN3 gene: https://www.malacards.org/search/results?q=ACTN3%20gene%20and%20Spinal%20Muscular%20Atrophy%20(SMA) A 2015 MRI revealed ankylosing spondylitis, multiple Tarlov cysts, stenosis at L4 and L5, spinal canal narrowing, and widespread degenerative changes. Surgery on L4 and L5 ...
Read more

Polio and Post-Polio Syndrome (PPS): Summary and Key Insights

By
Image
  In the human body, poliovirus can survive and replicate for varying durations depending on the phase of infection and the individual's immune response: Incubation Period : After entering the body, poliovirus can begin replicating in the throat and intestines within a few hours. The typical incubation period lasts 7 to 10 days (but can range from 3 to 35 days ), during which the virus is actively multiplying. Shedding in Feces : Even after symptoms have resolved or in asymptomatic cases, poliovirus can be excreted in the feces for an extended period. In most individuals, the virus is shed in feces for 4 to 8 weeks after infection. In rare cases, especially in individuals with compromised immune systems, the virus may persist in the gut and be shed for months or even years (a condition called chronic excretion ). Bloodstream : If the virus enters the bloodstream and causes viremia, it may persist there for a few days before being cleared by the immune system or progressing to ...
Read more

Cytokine Storm, Mast Cell Activation Syndrome (MCAS), Endothelial Dysfunction and microclots/thrombosis?

By
Update: New Research Builds on Previous Findings Cytokine Storms in COVID-19, Hemophagocytic Lymphohistiocytosis, and CAR-T Therapy https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2832234?utm_source=silverchair&utm_medium=email&utm_campaign=article_alert-jamanetworkopen&utm_content=wklyforyou&utm_term=040925&adv= Conclusions: This recent cohort study builds upon earlier work by identifying COVID-related cytokine storm (COVID-CS) through common inflammation markers and comparing it with two other cytokine storm (CS) conditions: malignancy-associated hemophagocytic lymphohistiocytosis (MN-HLH) and CAR-T–associated cytokine release syndrome (CAR-T CRS) . Among the three groups, patients treated with CAR-T therapy showed the highest survival rates , in contrast to those with COVID-CS and MN-HLH. Interestingly, the study found that CAR-T CRS and COVID-CS share similar cytokine activation pathways , suggesting a comparable immune response mechanism. In c...
Read more

Introduction to Adenosine and Tachycardia

By
What is Adenosine? Adenosine is a chemical found in human cells, existing in three forms: adenosine, adenosine monophosphate (AMP), and adenosine triphosphate (ATP). Adenosine is a chemical found in the body that plays many roles, including influencing heart rate and promoting sleep and relaxation. It is also used as a medication to manage certain types of tachycardia, particularly supraventricular tachycardia. Adenosine works by slowing the heart rate through its action on the cardiac tissue. Adenosine production in the body occurs through multiple pathways: Phosphorylation of Adenine: Adenine can be directly phosphorylated to form AMP (adenosine monophosphate), which is then converted to ATP, ADP, and finally adenosine through dephosphorylation reactions. Breakdown of ATP: Adenosine is primarily formed in the body through the breakdown of ATP, which releases energy. ATP can be dephosphorylated stepwise through the action of various enzymes: ATP is first converted to ADP (adeno...
Read more

The Impact of Acids on Muscular and Vascular Systems: Potential Negative Outcomes

By
This is ongoing research, and updates will be included as soon as they become available. Acids, whether from external sources (like industrial chemicals) or internal imbalances (such as metabolic disorders), can have profound effects on both the muscular and vascular systems.   Exposure to strong acids or acid imbalances in the body can disrupt cellular function, cause tissue damage, and lead to systemic health problems. This article explores how acids can negatively impact muscular and vascular health, with an emphasis on both external exposure to corrosive acids and internal acid imbalances caused by metabolic disorders or genetic conditions. Since not everyone is affected by ME/CFS or COVID, it could be beneficial to test for genetic predispositions, such as amino acids, particularly fatty acids. 1. External Acid Exposure and Its Effects on Muscular and Vascular Systems 1.1. Muscular Effects Muscle tissue is highly sensitive to changes in pH, and exposure to strong acids ca...
Read more